

USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2024 TO 9/30/2025

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
UNIT: Mitchell Cancer Institute							
USA Health Clinical Trials							
Abdalla,	Ahmed	NIH	A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS	A24-0118-002	Continuation	9/30/2025	\$50
Alkharabsh	Omar	ABVI	Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance	A21-0019-003	Continuation	9/30/2025	\$3,430
Alkharabsh	Omar	LOXOI	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus	A22-0041-004	Continuation	9/30/2025	\$14,764
Alkharabsh	Omar	BMSI	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND	A24-0242-001	New	3/19/2025	\$0
Dyess,	Donna	GNTC	B59	A18-0198-008	Continuation	9/30/2025	\$9,330
How ard,	John	MERCK	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Follow ing	A21-0219-005	Continuation	9/30/2025	\$6,231
How ard,	John	NIH	S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide	A23-0095-004	Continuation	9/30/2025	\$45,900
Imran,	Hamayun	NIH	Work Order to the Master sub-aw ard agreement for Non Industry funding - Per Case Reimbursement	A19-0217-004	Continuation	9/30/2025	\$500
Imran,	Hamayun	NIH	CHOP w orkload Intensity U10CA180886 NCTN Operations grant.	A21-0184-006	Continuation	9/30/2025	\$500
Imran,	Hamayun	NIH	PER CASE REIMBURSEMENT NCTN Operations Grant U10CA180886	A21-0185-006	Continuation	9/30/2025	\$13,450
Imran,	Hamayun	PHI	CHILDREN'S ONCOLOGY GROUP PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955Per Case Reimbursement (PCR)	A21-0228-003	Continuation	9/30/2025	\$2,500
Imran,	Hamayun	SBLD	St. Baldrick's Foundation supplement per case reimbursement.	A22-0212-003	Continuation	9/30/2025	\$1,250
Imran,	Hamayun	NIH	AH	A23-0201-002	Continuation	9/30/2025	\$4,600

USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2024 TO 9/30/2025

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Jones,	Nathaniel	MERCK	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without	A21-0119-005	Continuation	9/30/2025	\$19,319
Jones,	Nathaniel	KGB	A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With Hlgh-Grade Serous Ovarian	A23-0174-003	Continuation	9/30/2025	\$35,726
Jones,	Nathaniel	GOG	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus	A24-0117-002	Continuation	9/30/2025	\$21,662
Khushman,	Moh'D	ABVI	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) inSubjects w ith Previously Treated c-Met+ Non-	A20-0061-005	Continuation	9/30/2025	\$3,370
Khushman,	Moh'D	NAT	BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer	A21-0065-005	Continuation	9/30/2025	\$29,120
Kilgo,	William	OCTAVE	Clinical utility and decision impact of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis retrospective	A24-0230-002	Continuation	9/30/2025	\$4,305
Mazloom,	Anita	BMSI	A Phase 3, Tw o-Stage, Randomized, Multicenter, Open-label Study Comparing CC-92489 (BMS-986348), Carfilzomib, and Dexamethasone	A23-0085-003	Continuation	9/30/2025	\$264,587
Munir,	Ayesha	NIH	NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DEESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT	A19-0254-001	New	9/9/2025	\$0
Nisar,	Taha	NIH	Saturn 3B:R26-S02	A20-0053-004	Continuation	9/30/2025	\$4,385
Nisar,	Taha	NIH	Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE) Study	A20-0175-003	Continuation	9/30/2025	\$14,525
Pai,	Sachin	MERCK	MCI Merck 5890-001 Ph 1 Solid Tumor	A20-0033-006	Continuation	9/30/2025	\$2,750
Persing,	Brian	NIH	A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer	A21-0037-004	Continuation	9/30/2025	\$5,100
Pierce,	Jennifer	GENE	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec follow ed by Platinum-doublet Chemotherapy and	A23-0109-003	Continuation	9/30/2025	\$49,045
Pierce,	Jennifer	IMMG	Randomized, multicenter, open-label, Phase 3 study of mirvetuximabsoravtansine in combination w ith bevacizumab versus	A23-0196-003	Continuation	9/30/2025	\$47,700

USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2024 TO 9/30/2025

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Pierce,	Jennifer	GOG	A Tw o-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in	A 24-0129-003	Continuation	9/30/2025	\$907
Prodduturv	Pranitha	BMSI	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant	A 20-0124-006	Continuation	9/30/2025	\$22,993
Rocconi,	Rodney	NRG	Member Institution Purchased Service Agreement NRG Oncology Foundation, Inc.	A 14-0009-004	Continuation	9/30/2025	\$100
Roth,	Tracy	PFIZ	A PHASE 3 STUDY TO INVESTIGATE THE SAFETY , TOLERABILITY , AND IMMUNOGENICITY OF REV ACCINATING PREGNANT	A 25-0152-001	New	9/2/2025	\$0
Saleemi,	Adeel	NIH	CAPTIVA - Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis	A 23-0155-002	Continuation	9/30/2025	\$29,925
Scalici,	Jennifer	GOG	A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH	A 23-0061-003	Continuation	9/30/2025	\$13,615
TOTAL FOR DEPARTMENT: USA Health Clinical Trials							\$671,639